Menus Subscribe Search

Follow us


Mosaic

fecal-bacteria

Fecal bacteria at 10,000x magnification. (Photo: Public Domain)

Medicine’s Dirty Secret: Fecal Transplants Are the Next Big Thing in Health Care

• May 20, 2014 • 4:00 PM

Fecal bacteria at 10,000x magnification. (Photo: Public Domain)

Bryn Nelson gets to the bottom of an emerging—and often shocking—therapy.

This is how far a mother will go.

Your daughter has been sick for more than four years with a severe autoimmune disease that has left her colon raw with bloody ulcers. After multiple doctors and drugs have failed, you are frantic for her to get better. Then you send her disease into remission, virtually overnight, with a single act of love. “Who wouldn’t do that for their daughter?” you say. It’s like a miracle, you say. “An overnight magic wand.”

You’ve agreed to do it again—twice—for strangers. You’ve seen first-hand how effective it can be and you felt so badly for the patients and their families. Had you donated blood or plasma, no one would blink. But this? You can’t tell anyone else about this because of how they might react.

There are more like you, men and women who have given their loved ones a remarkable reprieve from a group of chronic conditions known as inflammatory bowel disease. There are many more who have cured patients of a potentially fatal bacterium known as Clostridium difficile. This microbe can persist in a cocoon-like spore for up to five months, impervious to nearly everything except bleach. It is fast becoming resistant to every antibiotic thrown at it.

You insist on “Marion” as a pseudonym. You say of your daughter’s therapy: “I don’t talk with anybody about it. I’ve told people that we replaced her…” and you pause, “unhealthy bacteria with healthy bacteria. I didn’t go into specifics.”

Here are the specifics: You were the donor in a fecal microbiota transplant. You gave your daughter your poo.

When a doctor, relative, or close friend touts the benefits of a fecal transplant, the message is likely to clash with the voices of our ancestors shouting just the opposite.

POO IS A DECIDEDLY IMPERFECT delivery vehicle for a medical therapy. It’s messy. It stinks. It’s inconsistent, not to mention a regulatory nightmare. But it can be incredibly potent. A classic study of nine healthy British volunteers found that bacteria accounted for more than half of the mass of their fecal solids. That astonishing concentration of microorganisms, both living and dead, makes sense when you consider that the microbial colonists inhabiting our gastrointestinal tract outnumber our own cells roughly three to one, on recent estimates.

In the ideal conditions of the human gut, a thriving ecosystem of 1,000 or more bacterial species that rivals the complexity of a rainforest has co-evolved with us. This microscopic jungle is constantly adapting in response to our diet, antibiotic use and other environmental influences. As the science has progressed, researchers are now comparing the entire collection of microbial inhabitants of the human gut, our microbiome, to a “hidden metabolic organ.” Scientists have linked disruptions to this organ, a condition known as dysbiosis, to everything from inflammatory bowel disease and high blood pressure to diabetes and obesity.

Viewed in this light, a fecal microbiota transplant is nothing more than an attempt to reseed an intestinal tract, often after antibiotics have killed off the native flora that might have kept invasive species at bay. No other medical therapy can claim such a high cure rate for the infection widely known as C. diff.

Some doctors have likened the recoveries of desperately ill patients to those seen with anti-HIV protease inhibitors in the mid-1990s. After the Mayo Clinic in Scottsdale, Arizona, performed its first fecal microbiota transplant in 2011, a patient who had been bed-ridden for weeks left the hospital 24 hours later. And in 2013, researchers in the Netherlands halted a landmark C. diff. clinical trial early for ethical reasons when they saw that the overall cure rate of 94 percent with donor feces had far outpaced the 31 percent cured with the antibiotic vancomycin.

Yet few other interventions elicit such disgust, revulsion, and ridicule. Chronicling a potential advance by a team of Canadian scientists, one newspaper account warned readers: “Hold your nose and don’t spit out your coffee.” In 2013, the founder of a patient advocacy blog called The Power of Poop wrote an open letter to 13 gastroenterology associations detailing the story of a Kentucky man who contracted an acute case of C. diff. Despite his family’s pleas, his doctor dismissed the idea of a fecal transplant as “quackery.” The man died the next day.

What’s behind this knee-jerk aversion? Perhaps, as one epidemiologist believes, it’s the voice of our evolutionary ancestors, warning us away from a major source of parasites and other pathogens. Perhaps, says another researcher, it’s the fading of an agrarian life that equated manure with opportunity, whose cultural influence is now drowned out by public health warnings of diarrhea-borne epidemics in towns and cities.

With the last lines of antibiotic defense beginning to crumble, however, getting past the cognitive dissonance of healthy poo as powerful curative could be a matter of life or death for tens of thousands of patients.

THIS IS HOW BAD a C. diff. infection can be.

Thursday morning, she’s a healthy 56-year-old kindergarten teacher. She has a bad back from decades working as a waitress, sure, and she smoked before quitting in her 30s when she was raising two boys on her own. The chronic inflammation in her shoulder occasionally flares and she’s put on a few pounds over the years, but she’s a typical mother from a big Irish Catholic family in Brooklyn. She has low blood pressure. She’s studying for a master’s degree in education.

She’s as tough as nails, her sons say.

She doesn’t feel well after school, though, so she goes to bed early. Then the diarrhea begins, at 4 a.m., with a sudden urgency. She takes her first sick day in memory. Her sons bring her Gatorade, and she’s still herself on the outside, despite being weak and tired and pale. Only something horrible is happening on the inside, made worse by the strong anti-diarrhea drugs that her doctor prescribed. Her intestines are steeping in a toxic stew released by millions of proliferating bacteria.

By Tuesday evening, she’s the sickest patient in the hospital. She’s craving a Diet Pepsi, but her infection has progressed so far that she has toxic megacolon: Her large intestine is dying. An unapologetically frank surgeon will remove it in a last-ditch attempt to save her life. She’s going into septic shock. Dozens of friends and family members crowd into the waiting room in a stunned vigil.

And it won’t be enough.

By Wednesday evening, at 7.20 p.m., Peggy Lillis will be gone, leaving her reeling sons to wonder how she could have died so quickly from something they had never heard of.

Perhaps Peggy contracted the deadly infection in the nearby nursing home where she periodically visited her godmother. Perhaps it was from the dentist’s office, where she underwent a root canal, was treated for an abscess and was prescribed clindamycin, a broad-spectrum antibiotic that can profoundly alter the gut microbiome and clear the way for C. diff.

The infection progressed so quickly that a fecal transplant–even if her sons had heard of it–may not have helped. “But I think the key thing here,” says her oldest son, Christian, “is that the disease itself and our ability to raise awareness of it and talk about it, identify it, prevent it, treat it, is all complicated by the fact that we don’t want to talk about shit.”

In 2010, Christian and his brother, Liam, co-founded the Peggy Lillis Memorial Foundation to focus more attention on an infection that has long outgrown its reputation as a nuisance in hospitals and nursing homes. “To me, it’s a really big public health crisis and one that we’re not talking about,” Christian says.

He has since ruffled feathers on an online C. diff. support group by suggesting that descriptions of symptoms shouldn’t be relegated to a folder labeled “TMI” (too much information) and pushed so far down the message board that he likens it to the sub-basement. “If you were hemorrhaging from the eyes or if you had a weird rash, you’d be like, ‘Here’s a picture,’” Christian says. “Does the breast cancer support group say, ‘We don’t want you to discuss what your tits look like’? It just doesn’t make any sense.”

Why should poo be any different, he says, especially when its description could provide crucial information about someone’s condition?

THE FIRST KNOWN RECORD of fecal transplants dates back to 4th-century China, when a doctor named Ge Hong included several mentions in his ambitious collection of therapeutic formulas, Zhou Hou Bei Ji Fang (in English, variously translated as Prescriptions Behind the Elbow for Emergency or Handy Therapy for Emergencies). Ge dutifully described how to treat patients with food poisoning or severe diarrhea by feeding them a fecal suspension bluntly named “solution of stool.”

Faming Zhang, a gastroenterologist at Nanjing Medical University in China, has researched the method’s history and writes that the treatment was deemed a “medical miracle that brought patients back from the brink of death.” As the practice spread, however, subsequent doctors may have felt the need for more euphemistic terminology. By the 16th century, when Chinese doctor and herbalist Li Shizhen wrote his influential compilation of herbal remedies, Ben Cao Gang Mu (Compendium of Materia Medica), he recorded a variety of names for the practice. While “fermented solution of stool” left little to the imagination, “yellow soup” and “golden juice” suggested more opaque prescriptions.

“What is currently done is kind of medieval, and that’s how I started. You plop a turd in the blender and draw it up in a syringe. Voila! There’s your transplant.”

In a 2012 letter in the American Journal of Gastroenterology, Zhang elaborates on the expanding list of applications in the Ming dynasty. He writes: “Li Shizhen described a series of prescriptions using fermented fecal solution, fresh fecal suspension, dry feces or infant feces for effective treatment for abdominal diseases with severe diarrhea, fever, pain, vomiting, and constipation.”

Similar methods began to catch on with European veterinarians and physicians. In the 17th century, Italian anatomist Girolamo Fabrizio described a simple technique in cows, sheep, and other ruminants that required only the transfer of chewed food from a healthy animal to a sick one to treat gastrointestinal disorders. Veterinarians now call this therapy “transfaunation.” The process, of course, also transfers bacteria, protozoa, and fungi. Veterinarians use a siphon to transplant the contents of a donor animal’s rumen, its first stomach compartment, to a recipient, much like a motorist might siphon petrol into an empty fuel tank.

In 1696, German physician Christian Franz Paullini penned his notorious and immensely popular Heilsame Dreck-Apotheke (Salutary Filth-Pharmacy). Paullini compiled hundreds of prescriptions from the medical literature and his own practice, all devoted to the curative powers of feces, urine, and other bodily secretions ranging from menstrual blood to earwax. Among his many recipes, he included one that used poo to treat dysentery.

One of the first indications that microbial therapy might help re-balance the human gut arrived in 1910, when the Journal of Advanced Therapeutics reported briefly on a new technique for treating “chronic intestinal putrefactions.” The journal described how a doctor had treated the intestinal disorder by injecting Bacillus bacteria into the rectum of each patient every four days, leading to a noticeable shift in the resident bacterial population.

Nearly 50 years later, a doctor named Ben Eiseman, chief of surgery at the Denver Veterans Administration Hospital, used fecal enemas to cure three men and one woman of a life-threatening inflammatory condition called pseudomembranous enterocolitis. Although Eiseman linked the intestinal disease to a well-known pathogen called Staphylococcus aureus, scientists now suspect the true culprit was C. diff. Amid the dry clinical language of his case reports, Eiseman recorded remarkably similar outcomes for each. “There was an immediate and dramatic response by this critically ill patient to a fecal retention enema,” he noted for the first. Nevertheless, he concluded, “enteric-coated capsules might be both more aesthetic and more effective.”

An ad hoc experiment involving capsules, in fact, was already underway on the East Coast of the U.S. at the direction of a surgeon who worried that the heavy use of pre-operative antibiotics was disrupting the normal intestinal flora of his patients. In 1957, the surgeon instructed a young bacteriologist named Stanley Falkow to begin collecting stool samples from surgical patients admitted to an unnamed hospital. Falkow, now a microbiologist and immunologist at Stanford University in Palo Alto, California, recalls dividing each patient’s poo into 12 large gelatin capsules before stashing the collection in a refrigerated ice-cream carton. The patients were then sent home with a prescription of two capsules per day in an attempt to re-establish their pre-surgical intestinal microbes.

Anecdotal reports at the time suggested that enrollees in this uncontrolled clinical trial were faring better than other post-surgical patients. But Falkow writes that they probably never knew what they were ingesting. The experiment came to an abrupt end when the chief hospital administrator found out and accused him of feeding patients their own shit.

Doctors have since developed more than half a dozen ways to transfer fecal microbes to their patients, but a more formal follow-up to Eiseman’s suggestion would have to wait another half-century.

IF YOU ASK PEOPLE from Burkina Faso, India, and the U.K. what disgusts them, chances are high that their lists will all include poo. “Probably of all of the elicitors of disgust that we’ve collected from studies around the world, that’s the most universal,” says Valerie Curtis, a self-described “disgustologist” and director of the Hygiene Centre at the London School of Hygiene and Tropical Medicine.

There’s a good reason for that “yuck factor,” she says. Researchers have identified dozens of common species of disease-causing organisms in our poo, ranging from parasites and amoebae to bacteria, fungi, and viruses. For our ancestors, Curtis hypothesizes, revulsion at that potent reservoir of disease may have been a matter of self-preservation. Those who didn’t stay away would have fallen ill more often, decreasing their chances of reproducing successfully.

It’s not just poo. Anything that comes out of another human body—blood, sweat, vomit, urine, semen, saliva—can elicit a fear-based feeling of disgust that it might get into yours, she says. “Because other people are the prime sources of the diseases that might make you sick, we really don’t want to have other people’s stuff inside us.” The same is true of our own secretions, once they’ve been expelled. “Try spitting in a clean glass, then drinking it!”

In her book, Don’t Look, Don’t Touch, Don’t Eat, Curtis argues that our inner defense mechanism probably extends to other signposts of disease: The sweaty, unkempt appearance of someone who is unwell; the smell of rotten food; the sight of rats, flies, and parasitic worms. If evolution has given us these rough signposts of revulsion, parents can effectively guide our distastes. When a mother exclaims “Yuck!” while narrowing her eyes to a squint and grimacing, her child learns that the object in question is best avoided.

As an emotion, Curtis says, disgust is so powerful that it can even trump love. When a doctor, relative, or close friend touts the benefits of a fecal transplant, the message is likely to clash with the voices of our ancestors shouting just the opposite.

Not all scientists are convinced that we harbor an innate predisposition to be grossed out by things like poo. Paul Rozin, professor of psychology at the University of Pennsylvania (widely known as Dr. Disgust), led a particularly vivid exploration of the indiscriminate tastes of toddlers in a series of experiments from the 1980s. More than half of his study subjects under the age of two readily ate a dish introduced as “dog poo”—actually peanut butter with Limburger and blue cheese. Older kids, however, were less likely to gobble it up, suggesting they had since learned what not to eat.

Canadian veterinarian and epidemiologist David Waltner-Toews suggests in his own book, The Origin of Feces, that our response to poo may instead reflect a complicated and contradictory cultural history based more on geography. Whereas feces was traditionally associated with fertiliser in rural agricultural areas, he says, it took on a more sinister role in urban centres as public health officials emphasised the very real danger of diarrheal diseases.

Call it the cow manure versus cholera dichotomy. “The further we get from the farm, the more we see only the threats and less the opportunities,” says Waltner-Toews, professor emeritus of epidemiology at the University of Guelph in Ontario. Excrement becomes a problem, rather than a potential solution.

Waltner-Toews says that kind of cultural “split personality” still exists, though often in a slightly different form. Doctors frequently talk about fighting a war against disease—a straightforward “us versus them” story. But the science of the microbiome has confounded that analogy and dragged it into murkier narratives about maintaining a healthier ecological balance, instead of wiping out the enemy. “It all starts to sound a little flaky and New Age-y,” he says.

Researchers have pointed out other dichotomies as well, like the “out of sight, out of mind” concept that makes us more disgusted by the notion of transplanting an external organ, like an eye or a tongue, than an internal one, such as a liver or kidney.

Regardless of the reasons for our collective disgust, the fear of losing a loved one may be an effective antidote. Aversion to diarrhea might help a mother in Bangladesh avoid becoming infected with cholera, but still she clings to her severely dehydrated toddler out of desperate, terrified love as she seeks help. Why shouldn’t the same be true for a mother caring for a daughter gravely ill with C. diff.? Perhaps she would even become a fecal donor if she could. In fact, doctor after doctor agrees that most patients with a serious gastrointestinal condition—and their families—are beyond caring that a little more poo may be involved in a therapeutic intervention; they’ve already been through far worse.

CATHERINE DUFF IS DEATHLY afraid of two things: public speaking and crickets. Poo, however, has long since ceased to disgust her. “That dissipates so quickly when you’re dying,” she says. Since 2005, she has had C. diff. eight times. The first six times, it responded to antibiotics. Then it didn’t. “My colorectal surgeon gave me the choice of having my colon removed or dying,” says Catherine, 58, from Carmel, Indiana. She had already lost a third of her colon and wasn’t about to give up any more.

With every bout of diarrhea and vomiting, she felt the life draining out of her. “I had basically resigned myself to the fact that I was going to die.” Then one of her three daughters, a corporate tax attorney, came across the research of an Australian gastroenterologist named Thomas Borody. His group was recording astonishing results in C. diff. patients with a therapy called fecal transplant.

Catherine read everything she could and brought the printouts to her doctors. By then, she had eight specialists. Only two, an infectious disease expert and a gastroenterologist, had ever heard of the technique. Neither was willing to try it.

And so in April 2012, Catherine became part of a burgeoning DIY movement born out of necessity. Her husband, John, a retired submarine commander who had frequently spent months at a time submerged with 180 other men, readily agreed to be her fecal donor. “Nothing grosses him out,” she says. They convinced her gastroenterologist to at least have John’s poo screened for pathogens, and then found a recipe and protocol on the Internet.

According to some of the more detailed how-to videos that have since popped up on YouTube, here’s what you need to do a fecal transplant at home:

  • A plastic container for collection
  • Latex gloves
  • A dedicated smoothie blender
  • A metal sieve
  • A disposable enema bottle
  • 0.9% saline solution
  • A large measuring cup
  • A plastic spoon

In its first six months, one of the more popular DIY videos was seen nearly 18,000 times.

Catherine recalls taking the enema at 4 p.m. “By 7, I felt good,” she says. “It was almost miraculous how quickly I felt better.” The next morning, she took a shower and got dressed, put on make-up, and went downstairs for breakfast, “things I hadn’t done in months,” she says.

Six months later, she had to undergo emergency surgery to correct a spinal cord compression caused by an old horseback riding accident. She came down with her eighth case of C. diff. before she ever left the hospital. But this time was different. This time, her colorectal surgeon agreed to try a fecal transplant using a colonoscopy—delivering the poo through a long, flexible tube inserted the length of her colon—and she became the first patient in the state of Indiana to undergo the procedure at a medical facility. “By the time I woke up from the sedation, I felt fine,” she says.

Officials at the U.S. Food and Drug Administration (FDA) were increasingly feeling otherwise. Struggling over how to regulate the procedure, they labeled it a drug instead of a transplant in April 2013, a move that dismayed patient advocates and sharply curtailed the fledgling field. Providers wanting to continue treating patients would have to file an Investigational New Drug application, an arduous and time-intensive requirement that most individual physicians were ill-equipped to meet.

Poo is a decidedly imperfect delivery vehicle for a medical therapy. It’s messy. It stinks. It’s inconsistent, not to mention a regulatory nightmare. But it can be incredibly potent.

A month later, the FDA hosted a public two-day workshop on the therapy in Bethesda, Maryland. Catherine, who had just launched the Fecal Transplant Foundation to connect patients with providers and encourage more doctors to offer the treatment, was one of 150 participants. When she scanned the list of attendees, she saw that she was the only patient. Midway through the meeting, she realized there would be no discussion about the impact from a patient’s perspective, and she knew she had to do something. So she wrote an impromptu speech on her iPad over lunch and tearfully begged the moderator to let her talk during the Friday afternoon session.

Just the thought of speaking to the entire group made her hyperventilate. But she signaled the moderator, as he had instructed, and her microphone lit up. Red. She began to tell her story, haltingly. “I was crying. I was so emotional and I was so scared.” She didn’t finish her speech, but it didn’t matter by then. She received a standing ovation from the doctors in the room. Afterwards, she found herself at the end of a reception line. “All of these doctors lined up to introduce themselves and to thank me,” she says. Within a few weeks, she had assembled the majority of her foundation’s board of directors and board of advisers.

Perhaps Catherine’s testimony helped sway the FDA. Perhaps it was the deluge of bad press that caught the agency off-guard as it struggled to balance the growing evidence of benefits with a highly variable and virtually unregulated practice that had flown beneath the radar. On June 18, 2013, the FDA bowed to pressure and partially reversed course, agreeing to exercise “enforcement discretion” for fecal microbiota transplants used to treat C. diff infections that weren’t responding to standard therapy. They wouldn’t be FDA-approved, in other words, but neither would they be prohibited.

Since the small victory, Catherine and her foundation have continued to push for more fecal microbiota transplant (FMT) clinical trials aimed at other digestive disorders, more research funding and more public awareness and education. She and a few board members who share her sense of humor have also begun crafting slogans that might eventually adorn T-shirts or sweatshirts. Her favorites? “Poop Is the Sh*t!” and “Give a Sh*t. Donate to the Fecal Transplant Foundation.” Her site also features an FMT awareness ribbon. It’s brown.

“It is what it is,” she says with a laugh. “There’s no way around what we’re talking about or what we’re dealing with.”

In Melbourne, Australia, a grateful transplant recipient named Tracy McGowan recently launched another pro-FMT website called The Power of Poop. While her own story is complicated by a host of chronic conditions, she says, those she posts on her site from other FMT recipients are often far more straightforward. Most write about recovering from C. diff. or sending their Crohn’s disease or ulcerative colitis into remission. An Ecuadorian doctor recalled how, before his own treatment for ulcerative colitis, with his wife as his donor, he had contemplated suicide.

Despite the ubiquity of home remedies, including Catherine’s first DIY fecal transplant, both she and Tracy stress that a medically supervised procedure is far more preferable, due to the potential for disaster in patients who do not properly screen their donors. Because so many patients are still struggling to find doctors willing to perform a transplant, however, Catherine is hoping to develop a more comprehensive online database of providers who can help.

THE UNASSUMING ONE-STORY office building on the periphery of the Wellswood neighborhood in Tampa, Florida—a discreet concrete box with windows constructed from privacy glass blocks—houses two gastroenterologist practices. One of them, RDS Infusions, is among the few places in the entire Southeastern U.S. where people with C. diff. can go for treatment. The process begins at an endoscopy center less than a mile away, where donor poo is inserted into sedated patients: up one end through a colonoscope and down the other through an endoscope that extends past the throat and stomach to the jejunum—the midsection of the small intestine.

The three- or five-day process ends back here in the office, on a bed that slopes downward toward the head, allowing gravity to help patients retain their follow-up fecal enemas. In one of the rooms, a small laminated poster depicts a rainbow arcing through a cloudbank and a single word repeated eight times in progressively bigger letters: “BREATHE.”

Among the 60 or so C. diff. patients that have followed his directives, R. David Shepard, a gastroenterologist in Tampa, says he hasn’t had a failure yet. Until the FDA forced him to put his ulcerative colitis program on hold, he had achieved a success rate of about 70 percent for that condition, he says. Marion’s daughter was the first.

Dressed casually in a light blue short-sleeve button-up shirt with black slacks, Shepard is cautious and unfailingly polite. He is soft-spoken with a subtle Southern accent and a steady gaze. At a table in a small kitchen behind the practice’s warren of rooms and narrow hallways, he describes his foray into a therapeutic field that he initially dismissed. Talk to half a dozen doctors, in fact, and you’ll begin to hear some common themes.

The first fleeting reference, whether in medical school or from a patient, is quickly brushed off.

“The thought of it was basically one of disgust and ‘Oh, I’ll never do that. You’ve got to be kidding,’” Shepard says.

Elaine Petrof, an infectious-disease specialist at Queen’s University and Kingston General Hospital in Ontario, says doctors in her specialty are often conditioned to associate infections with germs that must be eliminated. “Just conceptually speaking, pouring sewage into people doesn’t seem like a good idea, right?” she says. “I confess that I fell into that category until I saw what this can actually do for people’s lives and actually turn them around.”

The technique lingered on the margins of accepted medical practice for years because there simply wasn’t a great need for it, says Alexander Khoruts, a gastroenterologist and immunologist at the University of Minnesota in Minneapolis. That changed within the last decade, when C. diff. became an epidemic and a more virulent strain emerged from Quebec. Doctors now routinely encounter patients whose infections have stopped responding to all antibiotics.

A motivated, well-educated patient or family begs them to reconsider.

Most doctors still refuse to offer the procedure. “Five years ago or a little more, that was the end of the conversation,” Shepard says. But the Internet has changed everything. Now, he says, patients search until they find somebody who will do it.

They can also be persuasive. For Petrof, the turning point came in 2009. After a woman’s recurrent C. diff. infection stopped responding to antibiotics, she began bouncing in and out of the intensive care unit. Every day, the patient’s relatives asked Petrof to consider a fecal transplant. “I thought, ‘This is crazy,’” she recalls.

Then they brought her a bucket of poo.

The doctor finally yields.

“What completely floored me was the fact that within less than 72 hours, this patient, who had been having over a dozen bowel movements a day, basically completely turned around and at the end of the week walked out of the hospital,” Petrof says.

The therapy, using any of a range of methods, continues to work better than predicted.

“What is currently done is kind of medieval, and that’s how I started,” Khoruts says. “You plop a turd in the blender and draw it up in a syringe. Voila! There’s your transplant.” Some providers may send it up the colon, some down to the stomach or beyond, some—like Shepard—from both ends.

Although most providers haven’t published their overall success rates, their self-reported results are surprisingly similar, and consistent with what published reports there are. Khoruts says he has achieved a success rate of about 90 percent after one infusion, 99 percent after two. “In medicine, it’s pretty startling to have therapy that’s that effective for the most refractory patients with that condition,” he says. Colleen Kelly, a gastroenterologist with the Women’s Medicine Collaborative in Providence, Rhode Island, has performed the procedure on 130 patients with recurrent C. diff., with a success rate of about 95 percent. Most of the transplants have taken after just one attempt.

For a relatively simple bacterial infection, Petrof says, the potential remedy may be fairly straightforward. “With recurrent C. diff. what you’ve done is you’ve basically torched the forest,” she says. Nearly everything has been killed off by the antibiotics, leaving very low bacterial diversity. “So the C. diff. can just take root and grow.” Adding back almost any other flora—the equivalent of planting seedlings in the dirt—could help the ecosystem keep interloping pathogens at bay.

For more complicated conditions, though, a simple fecal transplant may not be enough, at least with donors from the Western world. One hypothesis suggests that people in lower-income countries might harbor more diverse bacterial populations in their guts than those who have grown up in a more sterile, antibiotic-rich environment. And in fact, a 2012 study found that residents of Venezuela’s Amazonas state and rural Malawi had markedly more diverse gut microbiomes than people living in three U.S. metropolitan areas. Scientists have already raised the idea that a rise in allergies and autoimmunity in industrialized nations may derive from a kind of collective defect of reduced microbial diversity.

“We cannot find people who’ve never been on antibiotics,” Khoruts says of his donors. For complex autoimmune diseases such as ulcerative colitis, fecal transplants may offer only a partial solution. And with some data suggesting that susceptibility may be linked in part to past antibiotic exposure, perhaps no Western donor can provide the microbes needed to fully reseed the gut.

What then? Khoruts says it may be necessary to seek out ancestral microbial communities—the ones all humans hosted before the advent of the antibiotic era—within people in Africa or the Amazon. “It’s just a disappearing resource,” he says.

Thomas Borody, founder and director of the Centre for Digestive Diseases in Sydney and a pioneer in the fecal transplant field, finds some merit in the notion that we should seek out a more natural human microbiome. Any donor-screening process, though, would have to account for endemic parasites and pathogens. And researchers, he says, still know very little about the components of this complex and variable organ that may derive its power not only from bacteria but also from fungi and viruses such as bacteria-infecting bacteriophages. “The shortest way of saying it is, ‘We don’t know shit, man.’”

COULD YOU BE A donor? Based on the most stringent selection criteria used by some doctors, you have to be screened for everything that would prevent you from donating blood, like HIV or hepatitis. You can’t be a gay man, or have had a tattoo within the past year, or have lived abroad for an extended period of time.

Catherine Duff is deathly afraid of two things: public speaking and crickets. Poo, however, has long since ceased to disgust her. “That dissipates so quickly when you’re dying,” she says.

You can’t have taken any antibiotics for the past three months—or better yet, six. You should also be thin, ideally, and with no history of autoimmune, neurological, or gastrointestinal diseases. You shouldn’t have any symptoms of metabolic syndrome, a group of conditions such as hypertension and high cholesterol that raise the risk of stroke, heart disease, and diabetes.

You can’t be squeamish.

Understandably, doctors often screen multiple candidates before they find a donor. Testing for pathogens alone can cost up to $800. Most of the fecal donor banks being established in clinics around the world still have donors in the single digits. Often, they consist of former patients’ relatives, like Marion, who have an established, successful track record.

Providers repeatedly stress the importance of careful donor screening. If an untested donor passed on a significant infection or condition, it could be devastating to the field as well as the recipient. With a growing body of evidence linking the microbiome to obesity, diabetes, and allergies, Khoruts also worries about the potential long-term impacts of poo from a donor with those conditions. “At this point, I think science tells us to be very cautious with this material,” he says.

Building up a bank of super-donors has not been easy. Given the rigid selection criteria, Khoruts has disqualified about 95 percent of respondents. “It turns out that healthy people are rare,” he says. So far, 17 volunteers have participated in his program, but only 10 are still actively donating.

OpenBiome, a new non-profit organization based at the Massachusetts Institute of Technology, is trying to help fill the void by providing pre-screened, filtered, and frozen poo at $250 a pop. Launched in September 2013, the bank had made 214 deliveries to 24 clinics in a dozen U.S. states and the Canadian province of British Columbia by the first week of April 2014. Based on early, unpublished results from 25 transplants, 23 succeeded in treating recurrent C. diff., according to co-founder and executive director James Burgess. So far, the group’s active donor pool includes just three people, all recruited through a network of friends and colleagues at MIT. Due to soaring demand, OpenBiome is hoping to double that number.

“Ultimately, I don’t think we’re going to be putting a whole stool in people, three to five years from now,” Colleen Kelly says. “And it’s not just because it’s not aesthetically pleasing, it’s more just because it’s really tough to try to find these donors.” Even if you’ve identified the perfect donor, how often can you really expect them to drop off their poo? “We don’t have farms with cows lined up in stalls.”

And there’s another wrinkle. When Khoruts screened a medical student who had responded to a flyer seeking donors, she told him her medical-school classmates reacted to her interest by laughing at her. “Nobody would giggle at a blood donor, right? You go donate blood. You could proudly put a button on, ‘I just donated.’ Everybody feels good,” he says. “You do that with a stool donor, everybody giggles. It’s embarrassing. And even though this person has just saved with one donation maybe three or four lives, which is far more than any blood donor can say, they get this peer pressure.”

That pressure may be unevenly applied throughout the world, however: Doctors in Australia and the Netherlands both say the “yuck factor” has been much less of an issue for them. Borody, who cites Eiseman’s once-obscure study from 1958 as one of his early inspirations, says he and his staff notify donors whenever their poo has been used to successfully treat a patient. The news often brings the donors to tears.

GIVE IT A DIFFERENT name. Dye it blue. Disguise the smell with lavender or citrus or pine. Take it out of its normal context and administer it amid stainless steel and clean glass surfaces. To minimize those ancestral voices of disgust, Val Curtis says, poo must be made more palatable.

Curtis recalls working with clinicians who told patients to collect their fecal samples in old margarine tubs. “And I said, ‘No wonder people won’t do it. You can’t associate poo with food, you’ve got to give them something clinical to collect it in,’” she says.

The same is true for the delivery, one reason Curtis says any method that discreetly encapsulates the poo into pills is likely to prove more acceptable. “Remember that our disgust system evolved for us to detect threats outside our bodies that want to get inside our bodies,” she says. That system may spring into action if a parasite crawls across your arm. But it won’t necessarily stop you from swallowing a triple-coated pill that releases its contents only when it has reached your intestinal tract. “You’re fooling the voices of your ancestors if you do put it into a capsule,” she says.

Or a “crapsule,” according to Borody’s daughter. His own poo-in-a-pill technique, he says, represents the therapy of the future, in large part because it avoids the need for a colonoscopy.

Despite her own success with fecal transplants, Petrof was uneasy about the “poop milkshakes” she was putting in her patients. “There’s got to be a better way to do this,” she thought. The result of her angst has been yet another alternative from a more defined subset of ingredients—essentially a mix of bacterial cultures.

She calls it a synthetic stool. Or “rePOOPulating” the gut.

It smells, well, different. At least that’s what the endoscopy nurses tell her. Unpleasant, but not as bad as the real thing. The cloudy white liquid in a small syringe just doesn’t seem as gross. More importantly, the synthetic stool infusions worked for two C. diff. patients in a recent proof-of-principle study.

Petrof concedes that her technique’s feasibility remains to be seen. For one thing, the bacterial mix requires a finicky growing environment dubbed a “robogut”: something akin to an artificial colon. She also believes her team may have stripped down the mixture a bit too much when it retained only 33 bacterial strains.

Health Canada’s regulatory officials have since put Petrof’s therapy on hold pending the outcome of more tests and have asked whether it’s possible to simplify her slurry even more. “So that looks like a total nightmare to them, but if you’re using principles of microbial ecology, which is kind of what this is based on in the first place, then you want a robust community.” And that probably means more, not less, diversity.

“We’re trying to maneuver our way through this rather muddy water,” she says. In the interim, she has reverted back to conducting faecal transplants.

In the U.S., OpenBiome and providers like Kelly have openly called for poo used in fecal transplants to be regulated as a tissue (like blood), not as a drug. In February 2014, however, the FDA seemed to reverse course again with a draft guidance that OpenBiome’s Burgess calls “substantially more restrictive” than the existing enforcement discretion. Among other stipulations, the policy would require all poo to be obtained “from a donor known to either the patient or the treating licensed health care provider,” posing a major challenge to OpenBiome’s banking model and alarming people, including Catherine Duff and other patient advocates.

Despite the uncertain path forward, more than a few clinicians have glimpsed the future of medicinal poo, and it is golden. Just weeks after a research team from the University of Calgary in Canada announced its own take on the feces-filled capsule method, dubbed “poop pills” by the press, Shepard brought the new technique to Tampa. He filled 35 triple-coated capsules with donor poo and used them to successfully treat a nursing-home patient on her fourth bout of C. diff.

“There’s so much going on in the whole human microbiome right now, there’s so much research, that I personally think this is just the tip of the iceberg,” he says. “What we’re doing right now with these fecal transplants is a very crude method of what we’ll probably be doing with patients in five to 10 years.”

By the beginning of April 2014, nearly 30 fecal transplant clinical trials were underway around the world. Roughly half were aimed at C. diff., including two testing the therapy in combination with vancomycin, and another multi-center trial evaluating the effectiveness of fresh versus frozen donor poo.

As the therapy becomes more widely established, via something akin to a “poop pill” or “crapsule,” perhaps the infectious pool of C. diff. patients may start to dwindle. More clinicians, then, might feel emboldened to explore how our bowel flora may affect not only the gastrointestinal system but also the immune and neurological systems. At least a dozen trials are now investigating whether fecal transplants can help treat some form of inflammatory bowel disease, be it Crohn’s disease or ulcerative colitis. Another is looking into Type 2 diabetes, and one is even using lean donors to test fecal transplants on patients with metabolic syndrome. Researchers say it won’t be along before they’re joined by studies investigating whether the therapy might aid diseases like multiple sclerosis and autism.

Despite all the ridicule and aversion and shame, we can no longer deny the emerging power of poo. Perhaps it’s time to push past the disgust and start giving a shit. And doing so proudly.


This post originally appeared on Mosaic as “Medicine’s Dirty Secret” and is republished here under a Creative Commons license.

Bryn Nelson
Bryn Nelson is a former microbiologist who decided he’d much rather write about microbes than mutate them. Since launching his new career in science journalism, he has written for the New York Times, Nature, Scientific American, BBC Focus, and many other publications.

More From Bryn Nelson

A weekly roundup of the best of Pacific Standard and PSmag.com, delivered straight to your inbox.

Recent Posts

October 1 • 2:00 PM

Most People With Addiction Simply Grow Out of It. Why Is This Widely Denied?

The idea that addiction is typically a chronic, progressive disease that requires treatment is false, the evidence shows. Yet the “aging out” experience of the majority is ignored by treatment providers and journalists.


October 1 • 1:00 PM

Midlife Neuroticism Linked to Alzheimer’s Disease in Old Age

New research from Sweden suggests that the personality dimension is connected to who ultimately suffers from late-in-life dementia.



October 1 • 11:11 AM

The Creative Class Boondoggle in Downtown Las Vegas

On Tony Hsieh and the pseudoscience of “collisions.”


October 1 • 9:14 AM

Mysterious Resting State Networks Might Be What Allow Different Brain Therapies to Work

Deep brain stimulation and similar treatments target the hubs of larger resting-state networks in the brain, researchers find.


October 1 • 6:00 AM

Would You Like a Subscription With Your Coffee?

A new app hopes to unite local coffee shops while helping you find a cheap cup of good coffee.


October 1 • 4:00 AM

How to Plant a Library

Somewhere outside of Oslo, there are 1,000 newly planted spruce trees. One hundred years from now, if everything goes to plan, they’ll be published together as 100 pieces of art.



September 30 • 10:09 AM

Trust Is Waning, and Inequality May Be to Blame

Trust in others and confidence in institutions is declining, while economic inequality creeps up, a new study shows.


September 30 • 8:00 AM

The Psychology of Penmanship

Graphology: It’s all (probably) bunk.



September 30 • 6:00 AM

The Medium Is the Message, 50 Years Later

Five decades on, what can Marshall McLuhan’s Understanding Media tell us about today?


September 30 • 4:00 AM

Grad School’s Mental Health Problem

Navigating the emotional stress of doctoral programs in a down market.


September 29 • 1:21 PM

Conference Call: Free Will Conference


September 29 • 12:00 PM

How Copyright Law Protects Art From Criticism

A case for allowing the copyright on Gone With the Wind to expire.


September 29 • 10:00 AM

Should We Be Told Who Funds Political Attack Ads?

On the value of campaign finance disclosure.


September 29 • 8:00 AM

Searching for a Man Named Penis

A quest to track down a real Penis proves difficult.


September 29 • 6:00 AM

Why Do So Many People Watch HGTV?

The same reason so many people watch NCIS or Law and Order: It’s all a procedural.


September 29 • 4:00 AM

The Link Between Depression and Terrorism

A new study from the United Kingdom finds a connection between depression and radicalization.


September 26 • 4:00 PM

Fast Track to a Spill?

Oil pipeline projects across America are speeding forward without environmental review.


September 26 • 2:00 PM

Why Liberals Love the Disease Theory of Addiction, by a Liberal Who Hates It

The disease model is convenient to liberals because it spares them having to say negative things about poor communities. But this conception of addiction harms the very people we wish to help.


September 26 • 1:21 PM

Race, Trust, and Split-Second Judgments


September 26 • 9:47 AM

Dopamine Might Be Behind Impulsive Behavior

A monkey study suggests the brain chemical makes what’s new and different more attractive.


September 26 • 8:00 AM

A Letter Becomes a Book Becomes a Play

Sarah Ruhl’s Dear Elizabeth: A Play in Letters From Elizabeth Bishop to Robert Lowell and Back Again takes 900 pages of correspondence between the two poets and turns them into an on-stage performance.


September 26 • 7:00 AM

Sonic Hedgehog, DICER, and the Problem With Naming Genes

Wait, why is there a Pokemon gene?


Follow us


Mysterious Resting State Networks Might Be What Allow Different Brain Therapies to Work

Deep brain stimulation and similar treatments target the hubs of larger resting-state networks in the brain, researchers find.

Trust Is Waning, and Inequality May Be to Blame

Trust in others and confidence in institutions is declining, while economic inequality creeps up, a new study shows.

Dopamine Might Be Behind Impulsive Behavior

A monkey study suggests the brain chemical makes what's new and different more attractive.

School Counselors Do More Than You’d Think

Adding just one counselor to a school has an enormous impact on discipline and test scores, according to a new study.

How a Second Language Trains Your Brain for Math

Second languages strengthen the brain's executive control circuits, with benefits beyond words.

The Big One

One company, Amazon, controls 67 percent of the e-book market in the United States—down from 90 percent five years ago. September/October 2014 new-big-one-5

Copyright © 2014 by Pacific Standard and The Miller-McCune Center for Research, Media, and Public Policy. All Rights Reserved.